Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico
Objectives: To undertake an economic evaluation of denosumab in comparison with a mixed scenario consisted of zoledronic acid or no treatment if there is a contraindication to this agent due to severe renal impairment (Mix ZA/No tx) in patients with multiple myeloma (MM). Methods: The analysis adopted the perspective of the Mexican public health care system as a payer. This is a partitioned-survival five-stages semi-Markov model for a life-time horizon. We evaluated the frequencies of skeletal-related events (SREs) as well as the costs associated to drug acquisition/infusion, routine patient management, medical attention of SREs, treatment of serious adverse events, and anti-myeloma treatment. Results: Denosumab use was more expensive but also more effective, with incremental cost-effectiveness ratios of $13,942 Mexican pesos (MXN) per SRE avoided and $1,893 MXN per additional month of progression-free survival. In general, the model is robust. Conclusions: In patients with MM, denosumab represents a cost-effective intervention in comparison with the Mix ZA/No tx..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Gaceta Mexicana de Oncología - 21(2022), 2 |
| Sprache: |
Englisch ; Spanisch |
|---|
| Beteiligte Personen: |
Fernando Carlos-Rivera [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Economic evaluation. Cost-effectiveness. Denosumab. Zoledronic acid. Skeletal-related events. Multiple myeloma. |
|---|
| doi: |
10.24875/j.gamo.M22000227 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ027690385 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ027690385 | ||
| 003 | DE-627 | ||
| 005 | 20230307120112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.24875/j.gamo.M22000227 |2 doi | |
| 035 | |a (DE-627)DOAJ027690385 | ||
| 035 | |a (DE-599)DOAJ62a2300a54a94f639768686fae0194a8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Fernando Carlos-Rivera |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives: To undertake an economic evaluation of denosumab in comparison with a mixed scenario consisted of zoledronic acid or no treatment if there is a contraindication to this agent due to severe renal impairment (Mix ZA/No tx) in patients with multiple myeloma (MM). Methods: The analysis adopted the perspective of the Mexican public health care system as a payer. This is a partitioned-survival five-stages semi-Markov model for a life-time horizon. We evaluated the frequencies of skeletal-related events (SREs) as well as the costs associated to drug acquisition/infusion, routine patient management, medical attention of SREs, treatment of serious adverse events, and anti-myeloma treatment. Results: Denosumab use was more expensive but also more effective, with incremental cost-effectiveness ratios of $13,942 Mexican pesos (MXN) per SRE avoided and $1,893 MXN per additional month of progression-free survival. In general, the model is robust. Conclusions: In patients with MM, denosumab represents a cost-effective intervention in comparison with the Mix ZA/No tx. | ||
| 650 | 4 | |a Economic evaluation. Cost-effectiveness. Denosumab. Zoledronic acid. Skeletal-related events. Multiple myeloma. | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Jorge A. Guzmán-Caniupan |e verfasserin |4 aut | |
| 700 | 0 | |a Adolfo Hernández-Garduño |e verfasserin |4 aut | |
| 700 | 0 | |a Mónica Alva-Esqueda |e verfasserin |4 aut | |
| 700 | 0 | |a Therese Aubry-de Maraumont |e verfasserin |4 aut | |
| 700 | 0 | |a Luis M. Camacho-Cordero |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Gaceta Mexicana de Oncología |d Permanyer, 2021 |g 21(2022), 2 |w (DE-627)DOAJ078619882 |x 2565005X |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2022 |g number:2 |
| 856 | 4 | 0 | |u https://doi.org/10.24875/j.gamo.M22000227 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/62a2300a54a94f639768686fae0194a8 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.gamo-smeo.com/frame_esp.php?id=282 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1665-9201 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2022 |e 2 | ||